Biomarkers and prostate cancer progression.
Mike
M
Fillon
D051186:Armadillo Domain Proteins / Q000235:genetics; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics*; D001706:Biopsy; D015815:Cell Adhesion Molecules / Q000235:genetics; D056931:Cryptochromes / Q000235:genetics; D018450:Disease Progression; D004722:Endoribonucleases / Q000235:genetics; D006801:Humans; D015847:Interleukin-4 / Q000235:genetics; D008297:Male; D010750:Phosphoproteins / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D011237:Predictive Value of Tests; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality; D054411:Receptors, Leptin / Q000235:genetics; D013548:Sweden; D014481:United States
C411307:ARVCF protein, human; D051186:Armadillo Domain Proteins; D014408:Biomarkers, Tumor; C538963:CRY1 protein, human; D015815:Cell Adhesion Molecules; D056931:Cryptochromes; C515448:LEPR protein, human; D010750:Phosphoproteins; D054411:Receptors, Leptin; D015847:Interleukin-4; D004722:Endoribonucleases; C031956:2-5A-dependent ribonuclease